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Tissue type is a major modifier of the
5-hydroxymethylcytosine content of human genes
Colm E. Nestor,1,2 Raffaele Ottaviano,1,2 James Reddington,2 Duncan Sproul,1,2
Diana Reinhardt,2 Donncha Dunican,2 Elad Katz,1 J. Michael Dixon,1 David J. Harrison,1
and Richard R. Meehan1,2,3
1Breakthrough Breast Cancer Research Unit and Division of Pathology, University of Edinburgh, Western General Hospital, Edinburgh
EH4 2XU, United Kingdom; 2MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital,
Edinburgh EH4 2XU, United Kingdom
The discovery of substantial amounts of 5-hydroxymethylcytosine (5hmC), formed by the oxidation of 5-methylcytosine
(5mC), in various mouse tissues and human embryonic stem (ES) cells has necessitated a reevaluation of our knowledge of
5mC/5hmC patterns and functions in mammalian cells. Here, we investigate the tissue specificity of both the global levels
and locus-specific distribution of 5hmC in several human tissues and cell lines. We find that global 5hmC content of
normal human tissues is highly variable, does not correlate with global 5mC content, and decreases rapidly as cells from
normal tissue adapt to cell culture. Using tiling microarrays to map 5hmC levels in DNA from normal human tissues, we
find that 5hmC patterns are tissue specific; unsupervised hierarchical clustering based solely on 5hmC patterns groups
independent biological samples by tissue type. Moreover, in agreement with previous studies, we find 5hmC associated
primarily, but not exclusively, with the body of transcribed genes, and that within these genes 5hmC levels are positively
correlated with transcription levels. However, using quantitative 5hmC-qPCR, we find that the absolute levels of 5hmC for
any given gene are primarily determined by tissue type, gene expression having a secondary influence on 5hmC levels.
That is, a gene transcribed at a similar level in several different tissues may have vastly different levels of 5hmC (>20-fold)
dependent on tissue type. Our findings highlight tissue type as a major modifier of 5hmC levels in expressed genes and
emphasize the importance of using quantitative analyses in the study of 5hmC levels.
[Supplemental material is available for this article.]
Typically, mammalian DNA methylation involves the covalent
attachment of a methyl group to the 5-position of cytosine in
a CpG dinucleotide by a member of the DNA methyltransferase
(DNMT) family of enzymes. DNA methylation patterns are estab-
lished in early development by the de novo methyltransferases,
DNMT3A/B, and maintained after subsequent cell divisions by
the maintenance methyltransferase, DNMT1 (Bird 2002; Wu and
Zhang 2010). The ability to establish and maintain DNA methyl-
ation patterns is essential for normal development inmammals (Li
et al. 1992). Specifically, DNA methylation is involved in the
maintenance of genome integrity by silencing transposable ele-
ments (Walsh et al. 1998), the process of X-inactivation in females
(Lock et al. 1987; Sado et al. 2000), regulation of allele-specific
expression at imprinted loci (Plass and Soloway 2002), andmay be
involved in the regulation of single-copy gene expression (Borgel
et al. 2010). The genomic distribution of CpG methylation in the
human genome is highly non-random; whereas the majority of
CpGs are methylated, regions of high CpG density, termed CpG
islands, which often colocalize with gene promoters, are typically
unmethylated. How this dichotomous pattern of CpG methyla-
tion is maintained is unclear.
In a groundbreaking study, the DNA of mouse Purkinje neu-
rons and embryonic stem (ES) cells were found to contain signifi-
cant levels of themodified base 5-hydroxymethylcytosine (5hmC)
(Kriaucionis and Heintz 2009). A complementary study identified
the ten-eleven translocation (TET) protein, TET1, as an iron- and
a-ketoglutarate (a-KG)-dependent dioxygenase responsible for
catalyzing the hydroxylation of 5mC to 5hmC (Tahiliani et al.
2009). Subsequent studies have reported significant levels of
5hmC in many other mouse and human tissues (Globisch et al.
2010; Szwagierczak et al. 2010; Jin et al. 2011) and confirmed TET2
and TET3 as possessing enzymatic properties similar to that of
TET1 (Ito et al. 2010; Koh et al. 2011). Interestingly, the genesTET1
and TET2 were first identified as common targets of mutation in
Acute Myeloid Leukaemia (AML). Recently, Figueroa et al. (2010)
showed that mutation of the isocitrate dehydrogenase genes IDH1
and IDH2 led to the aberrant production of 2-hydroxyglutarate
(2-HG), a metabolite that inhibits TET2 enzymatic activity,
resulting in a hypermethylated promoter phenotype in AML tu-
mors carrying IDH1/2mutations. This hypermethylated promoter
phenotype overlapped with AML tumors carrying a TET2 muta-
tion only, highlighting a potential role for the TET family of pro-
teins in the epigenetic dysregulation observed in many cancers
(Figueroa et al. 2010). In addition, Tet1 knockdown in mouse ES
cells resulted in de novo methylation of the transcription start site
(TSS) of more than 100 genes, although the gain in 5mC was
modest (Williams et al. 2011).
Many of the techniques commonly used to assay 5mC, in-
cluding conventional methyl-sensitive restriction digest and the
widely used technique of bisulfite sequencing, are incapable of
distinguishing between 5mC and 5hmC (Huang et al. 2010; Jin
et al. 2010; Nestor et al. 2010). As such, the discovery of 5hmC
3Corresponding author.
E-mail richard.meehan@hgu.mrc.ac.uk.
Article published online before print. Article, supplemental material, and pub-
lication date are at http://www.genome.org/cgi/doi/10.1101/gr.126417.111.
Freely available online through the Genome Research Open Access option.
22:467–477  2012 by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/12; www.genome.org Genome Research 467
www.genome.org
necessitates not only its characterization in mammalian cells, but
also reevaluation of previously published 5mC data (Dahl et al.
2011). The recent development of 5hmC-specific antibodies and
5hmC-sensitive restriction digest-PCR (5hmC-qPCR) assays has
allowed for determination of genome-wide patterns and locus-
specific amounts of 5hmC levels, respectively (Davis and Vaisvila
2011; Jin et al. 2011).
The biological function of 5hmC is unknown. However,
several very recent studies of the genome-wide distribution of both
5hmC and TET1-binding in mouse ES cells have begun to illumi-
nate potential roles of both the mark and the proteins, which in
some cases may not only be separate, but conflicting. A role for
5hmC as an intermediate in DNA demethylation has been widely
postulated (Tahiliani et al. 2009;Wu and Zhang 2010). As 5hmC is
poorly recognized by DNMT1 (Valinluck and Sowers 2007),
methylation can be lost passively through successive cell divisions.
However, the rapid loss of 5mC from the paternal pro-nucleus in
the zygote and in primordial germ cells has long hinted at a process
of active demethylation in mammals (Mayer et al. 2000; Oswald
et al. 2000; Hajkova et al. 2002). It is hypothesized that conversion
of 5mC to 5hmC may serve as the first step in such a pathway by
providing a substrate for downstream repair pathways such as
mismatch (MMR) or base-excision repair (BER), which ultimately
replace 5hmC with cytosine (C) (Wu and Zhang 2010). In support
of this hypothesis, two recent reports have shown that the rapid
loss of 5mC frommouse paternal pro-nuclei is accompanied by an
accumulation of genome-wide 5hmC (Iqbal et al. 2011; Wossidlo
et al. 2011). However, the failure to find many of the predicted
intermediates of an active oxidative demethylation pathway by
mass-spectrometry analysis of normal mouse brain tissues chal-
lenges the existence of such a mechanism (Globisch et al. 2010).
The observations that 5hmC is enriched in the gene body of active
genes inmouse cerebellum (Song et al. 2010) and cannot be bound
by transcriptionally repressive methyl-CpG binding domain
(MBD) proteins in vitro (Valinluck et al. 2004; Jin et al. 2010)
strongly suggested a role for 5hmC in the regulation of transcrip-
tion. Gene-body 5hmC levels may regulate the transcription rate
by modifying the accessibility of genic chromatin to transcrip-
tional machinery or by inhibiting binding of repressive methyl-
CpG binding proteins (MBDs). However, work on mouse ES cells
suggests that the relationship between 5hmC and/or TET1 with
transcription is farmore complex (Pastor et al. 2011;Williams et al.
2011; Wu et al. 2011a,b). TET1 enrichment was often observed at
the transcription start site (TSS) of genes with high CpG density
(HCP) promoters marked by the bivalent histone signature of
histone 3 lysine 27 trimethylation (H3K27me3) and histone 3 ly-
sine 4 trimethylation (H3K4me3). This gene set is enriched for
transcriptionally repressed developmental genes. Moreover, the
repressive activity of TET1may be independent of its catalytic role,
because several genes up-regulated upon Tet1 knockdown in WT
ES cells were also up-regulated in ES cells lackingDNAmethylation
(Dnmt1/3a/3b/) (Williams et al. 2011). Consistent with these
observations, Wu and colleagues found 5hmC to be enriched in
the bodies of highly expressed genes and at the TSS of transcrip-
tionally inactive genes (Wu et al. 2011a). However, two simulta-
neous studies failed to report a significant association between
genic 5hmC and transcription levels or RNA polymerase II activity
(Pastor et al. 2011; Williams et al. 2011).
The majority of recent genome-wide studies of 5hmC and
TET1 have used the same model system, mouse ES cells. Thus, the
nature of locus-specific patterns of 5hmC within and between
normal tissues remains unknown. Here, we use tiling microarrays
and 5hmC-qPCR to investigate both global 5hmC content and
locus-specific patterns of 5hmC in several normal human tissues.
We find that unlike 5mC, global 5hmC content varies markedly
between tissues and does not correlate with global 5mC content.
Furthermore, the global 5hmC content of cell lines is markedly
reduced comparedwith levels in the corresponding normal tissues.
Significantly, we note that TET1/2/3 gene expression and conse-
quently 5hmC content is rapidly and significantly reduced upon
adaptation of cells fromnormal human tissue to cell culture. Using
an 5hmC-specific antibody and tiling microarrays to profile locus-
specific patterns of 5hmC,we found that 5hmCpatterns are tissue-
specific; allowing clustering of similar tissues based on 5hmC
profiles alone. In addition, using RNA-seq data for normal human
tissues, 5hmCwas found to be enriched in the gene bodies of active
genes, and the level of enrichment was positively correlated with
gene expression levels. Significantly, however, we also find that for
any given expressed gene, tissue type, not transcription level, is the
major modifier of absolute levels of 5hmC.
Results
Global 5hmC content of human tissues is variable and does
not correlate with total mC content or TET gene expression
PCR products of the mouse Tex19.1 promoter in which each cy-
tosine was either unmethylated (C), methylated (5mC), or
hydroxymethylated (5hmC) were used to test the sensitivity and
specificity of both the a-5mC and a-5hmC antibodies in immuno
dot-blot assays. Both antibodies exhibited specificity to their re-
spectivemarks andno cross-reactivitywas observed, even at higher
concentrations of DNA (Fig. 1A). The dynamic range of detection
of 5hmC implies that this assay can be usefully employed to de-
termine differences in the 5hmC content of different genomic
DNA samples.
Immuno dot-blots of DNA from eight normal human tissues
and one human embryonic stem cell (hESC) line (Shef-6) revealed
large inter-tissue variation in global 5hmC levels (Fig. 1B). In
agreement with previous studies, human brain had the highest
global levels of both 5hmC and 5mC (Song et al. 2010). Quanti-
fication of spot intensity by densitometric analysis further em-
phasized the scale of variation in global 5hmCbetween tissues. For
example, levels in brainwere about four times greater than those in
the next highest tissue, breast, and more than 1000 times greater
than the levels in blood or hESCs (Fig. 1C). The variation in inter-
tissue global 5hmC levels contrasted strikingly with global 5mC
levels, which varied little between tissues. Whereas the dot-blot as-
say could robustly detect the large inter-tissue differences observed
in global 5hmC levels, relative inter-tissue differences in 5mC were
more difficult to quantify with confidence due to the small inter-
tissue differences in global 5mC levels observed. To confirm the
apparent lack of association between global mC and hmC levels
determined by dot-blotting, the inter-tissue differences in 5hmC
determined here were compared with previously published global
5mC levels quantified by high-performance liquid chromatography
(HPLC) (Ehrlich et al. 1982;Weisenberger et al. 2005). No significant
correlation was found between global 5hmC and 5mC levels
(Spearman’s rho = 0.42; P = 0.35) (Fig. 1D). Interestingly, broadly
similar patterns of inter-tissue global 5mC and 5hmC levels were
conserved in mouse; brain and liver being highly enriched, whereas
blood, spleen, and ES cellswere relatively depletedof 5hmC(Fig. 1E).
To test the association between TET gene expression and
global 5hmC content, we determined the relative expression level
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of all three TET genes in 20 human tissues and human ES cells
(Supplemental Fig. S2A). Each tissue cDNA sample was generated
from RNAs pooled from at least three different individuals. The
relative expression of TET2 and TET3 between tissues was highly
similar to that reported in mouse (Ito et al. 2010). Human ES cells
are distinguished by their relative lack of TET2 and TET3 expres-
sion, suggesting that TET1 may be the primary dioxygenase re-
sponsible for generation of 5hmC in these cells. However, human
TET1 expression was just twofold higher in ES cells compared with
average expression in somatic tissues. This is markedly lower than
the 10-fold difference in Tet1 expression observed between ES cells
and somatic tissues in mouse (Ito et al. 2010). Our observation of
TET1 expression in human tissues is consistent with a previous
analysis of TET1/2/3 gene expression in 24 human tissues that
reported TET1 expression in half (12/24) of the tissues assayed
(Lorsbach et al. 2003). Interestingly, TET1/2/3 gene expression did
not correlate with relative global 5hmC content (Supplemental
Fig. S2B).
Cell culture results in a dramatic reduction of global
5hmC levels
Epigenetic dysregulation, including promoter hypermethylation
and genome-wide hypomethylation, is a hallmark ofmany cancers
(Esteller 2007). Moreover, several recent studies have reported
a direct link between TET inhibition and aberrant promoter
hypermethylation in AML (Figueroa et al. 2010; Xu et al. 2011).
Thus, we determined if global 5hmC levels in cell culturemodels of
several human cancers differed from that observed in their corre-
sponding non-cancerous tissues of origin.
We observed much lower global 5hmC in eight breast can-
cer cell lines and one primary human mammary epithelial cell
(HMEC) line relative to normal breast tissue (Fig. 2A,B). This re-
duction of global 5hmC in human breast cell lines wasmirrored by
significantly reduced levels of transcripts for all three TET genes
relative to levels in normal breast tissue (Fig. 2C). A similar re-
duction in global 5hmC levelswas observed in both colon and liver
cancer cell lines relative to levels in the corresponding non-can-
cerous tissues (Fig. 2D). Interestingly, DNA obtained from a pri-
mary HMEC line 1 wk after establishment from normal breast
tissue also showed a dramatic reduction in both global 5hmC
content and TET gene expression, suggesting that conversion to
cell culture may be sufficient to effect a global reduction in 5hmC
levels (Fig. 2A–C). This marked reduction in TET1/2/3 gene ex-
pression in culture was not observed between normal breast tissue
and breast tumors in three previously published independent
microarray studies, suggesting that the observed TET gene down-
regulation in culture may not be a cancer-associated process
Figure 1. Marked inter-tissue differences in global 5hmC levels. (A) Dot-blots of decreasing amounts of a PCR product of the mouse Tex19 promoter
sequence in which all cytosines are either unmodified (C ), methylated (5mC), or hydroxymethylated (5hmC), were probed with a-5hmC and a-5mC
antibodies. The a-5hmC and a-5mC antibodies are specific for their respective marks. (B) Duplicate dot-blots of DNA from human tissues and ES cells
probed with antibodies specific to 5hmC or 5mC show that global 5hmC levels vary markedly between normal human tissues. An a-ssDNA antibody was
used to control for loading; 500 ng and 100 ng were loaded in the upper and lower lanes, respectively. Ten nanograms of amplified mouse Tex19.1
promoter was used as a control; (solid circle) unmethylated DNA; (dotted circle) methylated DNA; (dashed circle) hydroxymethylated DNA. (C ) Inter-
tissue differences in global 5hmC levels as determined by densitometric analysis of dot-blots shown in panel B. 5hmC values were normalized to an ssDNA
loading control and scaled relative to brain. Values are the means of two independent biological replicates. Spleen and ES values represent single mea-
surements. (D) A scatterplot showing a lack of correlation between global 5mC and 5hmC values for seven samples. 5mC values were obtained from
previously published HPLC analyses of global 5mC content in human tissues (Ehrlich et al. 1982;Weisenberger et al. 2005). (E ) Duplicate dot-blots of DNA
from mouse tissues and ES cells probed with antibodies specific to 5hmC or 5mC show that global 5hmC levels vary markedly between normal mouse
tissues. An a-ssDNA antibody was used to control for loading. Ten nanograms of amplified mouse Tex19.1 promoter was used as a control; (solid circle)
unmethylated DNA; (dotted circle) methylated DNA; (dashed circle) hydroxymethylated DNA.
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(Supplemental Fig. S3) (Richardson et al. 2006; Turashvili et al.
2007; Chen et al. 2010). To further investigate this hypothesis, we
cultured cells from normal human breast tissue and analyzed the
changes in both global 5mC and 5hmC levels over time. Rapid loss
of 5hmC was apparent after 1 wk in culture (1 passage; 7 d), and
global 5hmC levels continued to decrease with each passage of the
cells. In stark contrast, global 5mC levels remained unchanged,
suggesting that the loss of 5hmC was not solely due to a concom-
itant loss of 5mC (Fig. 2E).
Locus-specific mapping of 5hmC in DNA from normal
human tissues
The marked difference in global 5hmC levels observed between
normal human tissues could reflect differences in locus-specific pat-
terns of 5hmC. A recent study of genome-wide 5hmC in mouse ES
cell DNA found that 5hmC immuno-precipitation combined with
genome-wide tiling microarrays could consistently and robustly
identify peaks of 5hmC in themouse genome (Wu et al. 2011a). Here
we used a combination of tiling microarrays and 5hmC-sensitive
restriction digest-qPCR (hmC-qPCR) to determine locus-specific
5hmCpatterns in several normal human tissues. As recent studies
have revealed that both intra- and intergenic regions of the mouse
genome can contain high levels of 5hmC, we used tilingmicroarrays
covering the ENCODE regions selected for their biological signifi-
cance, including theHOXA cluster,HBB,CFTFR, andAPO cluster. The
features representedoneach array are listed in Supplemental Table S3.
Using a candidate approach, we identified the promoter of
TEX14 and a differentially methylated region (DMR) of the H19
gene as enriched for 5hmC, whereas LINE-1 elements and the
promoter of GAPDH were relatively depleted. qPCR of these loci
were used to validate all hydroxymethylated DNA immuno-pre-
cipitation (5hmC-IP) assays (Supplemental Fig. S4A).
Unsupervised hierarchical clustering of 5hmC enrichment
values [log2(input/IP)] for all 72,000 probes on each array clustered
samples by tissue type, confirming that patterns of 5hmC are tis-
sue-specific and that inter-tissue variation in 5hmC patterns is
greater than inter-individual variation (Fig. 3A,B).
Peaks of 5hmC enrichment were defined as any five consec-
utive probes in which a minimum of four probes had an enrich-
ment score above the 75th percentile, yielding a false discovery
rate (FDR) <0.05. We term probes assigned to 5hmC peaks ‘‘peak-
probes.’’ Subsequently, using gene models from the RefSeq data-
base, each probe was classified according to its genic location—
Figure 2. Reduced global 5hmC levels and TET1/2/3 gene expression in human cell lines. (A) Duplicate dot-blots of DNA (500 ng) from normal human
breast tissue, a primary mammary epithelial cell line from non-cancerous tissue, and eight breast cancer cell lines probed with antibodies specific to 5hmC
or ssDNA illustrate that global 5hmC levels are reduced in the DNA of primary and cancer cell lines relative to normal breast. (B) Inter-sample differences in
global 5hmC levels by densitometric analysis of dot-blots shown in panel A. 5hmC values were normalized to the ssDNA loading control and scaled relative
to normal breast DNA. Values are themeans of two technical replicates. (C ) RT-qPCR analysis of expression levels of TET1, TET2, and TET3 in normal human
breast tissue, a primary mammary epithelial cell line, and eight breast cancer cell lines. Expression levels were normalized to GAPDH expression, and
expression levels in normal human breast set to 1. Error bars represent the SD of two technical replicates. (D) Duplicate dot-blots of DNA (500 ng)
from normal human colon and liver tissue and six cancer cell lines probed with antibodies specific to 5hmC or ssDNA illustrate that global 5hmC levels
are also reduced in the DNA of colon and liver cancer cell lines relative to normal tissue. (E ) Duplicate dot-blots of DNA (500 ng) from normal human
breast tissue, and the primary mammary epithelial cell line derived from that tissue probed with antibodies specific to 5hmC, 5mC, or ssDNA show
that global levels of 5hmC, but not 5mC, are gradually reduced upon transformation of normal breast tissue to cell culture. Ten nanograms of
amplified mouse Tex19.1 promoter in which all cytosines were either unmodified (C), methylated (mC), or hydroxymethylated (hmC), was used as
a control.
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promoter, intragenic, downstream, or intergenic, as illustrated in
Figure 4A (upper panel). Note that because repetitive sequences are
typically not represented on tiling microarrays, only the non-re-
petitive portion of each genic location is assessed here. Consistent
with previous studies in mouse ES cells, the genic distribution of
peak probes differed significantly from that expected by chance
(x2-test; P < 0.001) being enriched in intragenic regions and pro-
moters (Fig. 4A, lower panel). However, it is interesting to note that
;25% of 5hmC peaks are not located within annotated genes and
their proximal flanking sequences. To further investigate the ob-
served association of 5hmC enrichment and gene bodies, we an-
alyzed the overlap between 5hmC peak-probes and previously
published total RNA-sequencing reads for normal human brain,
breast, colon, liver, and testis (Ramskold et al. 2009). We find that
peak-probes preferentially colocalize with RNA-seq reads in all
tissues (Fig. 4B) and that the 5hmC level of probes is positively
correlated with transcription, as measured by the number of
overlapping RNA-seq reads (Fig. 4C). Interestingly, although the
association of 5hmC levels with gene transcription within tissues
is striking at some loci (Fig. 4D; Supplemental Fig. S5), it does not
explain the patterns of 5hmC observed at many other loci (Sup-
plemental Fig. S6). Indeed, although significantly correlated,
transcription (number of overlapping reads) explained <1% (i.e.,
brain; r2 = 0.0025, P = 0) in the variation in 5hmC values in each
tissues assayed
As tiling microarrays are limited in their ability to represent
non-unique sequences, we determined the 5hmC enrichment of
several repetitive elements by 5hmC-IP followed by qPCR. SINE
elements (Alu), LINE-1 elements, and satellite sequences (Sat2 and
Sata) were all relatively depleted of 5hmC in both normal tissues
and cancer cell lines (Supplemental Fig. S7A). Thus, whereas much
of the total 5mC content of a normal human genome is found in
the repetitive fraction, 5hmC appears largely occluded from repeat
sequences. As ‘‘repeats’’may comprise >50%of the humangenome
and are usually methylated in normal somatic tissue, the relative
lack of global 5hmC compared with global 5mC in reports for
most normal mouse tissues may simply reflect a restriction of
5hmC to unique, transcribed sequences (Weisenberger et al. 2005;
Kriaucionis and Heintz 2009; Globisch et al. 2010).
Tissue type, not transcription level, is the major modifier
of 5hmC levels in genes
Whereas antibody-based enrichment of 5hmC-containing DNA
fragments allows for characterization of genome-wide 5hmC pat-
terns, it is difficult to relate the enrichment values obtained to
absolute levels of 5hmC, which can also be compromised by the
effects of DNA sequence composition on antibody affinity. We
used 5hmC-sensitive restriction digest-qPCR (hmC-qPCR) to de-
termine absolute 5hmC levels at 12 loci across (1) the HOXA
cluster, which showsmarked differences in 5hmCprofiles between
tissues, and (2) the H19 locus, which is among the most enriched
regions assayed in all tissues (Supplemental Figs. S5, S6). An outline
of the assay and sample calculations are presented in Supplemental
Figure S1. We tested the accuracy of the assay by spiking each ge-
nomic sample with synthetic 100-bp DNA templates containing
a single MspI site in which the internal cytosine was either un-
modified (C), methylated (5mC), or hydroxymethylated (5hmC).
Different ratios of each template type were added to different re-
actions. The expected %5hmC and experimentally determined
%5hmC levels were highly significantly correlated (Pearson’s cor-
relation; r = 0.96, P > 0.0001) over 10 independent experiments
(Supplemental Fig. S8A). In addition, technical and biological
replicates of both liver and brain samples were highly significantly
correlated over seven loci tested, showing that the results obtained
are highly reproducible (Supplemental Fig. S8B,C).
Marked variation in locus-specific 5hmC content was ob-
served between tissues; whereas the 5hmC content of loci in the
gene body of H19 varied between 37% and 70% in brain DNA,
values of just 0.9%–4.3% were observed in blood (Table 1). In
agreement with values obtained from tiling microarrays, each tis-
sue had consistently higher levels of 5hmC at loci in theH19/IGF2
region than those in the HOXA cluster, and genic loci in both re-
gions showed higher levels of 5hmC than non-genic loci (Sup-
plemental Fig. S9A,B). However, no significant correlation between
5hmC enrichment values determined on themicroarray and those
determined by 5hmC-qPCR was observed over the 12 loci tested.
The absence of significant correlation is not entirely unexpected
given that 5hmC enrichment values on the microarrays were de-
termined by immuno-precipitation of large DNA fragments (200–
Figure 3. Genomic patterns of 5hmC enrichment are tissue-specific. (A)
Shown are the patterns of 5hmC enrichment [log2(input/IP)] across the
HOXA cluster for multiple replicates of multiple tissues. (B) A dendrogram
derived from unsupervised hierarchical consensus clustering of 14 human
DNA samples based on 5hmC enrichment levels for all 72,000 probes on
each tiling microarray. Samples cluster by tissue type. AU (approximately
unbiased) P-value of robustness of each cluster; (**) P > 0.01; (***) P >
0.001.
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1000 bp) potentially containing numerous CpG dinucleotides,
whereas 5hmC-qPCR evaluates a single MspI locus within that
fragment, the 5hmC content of which may differ markedly from
that of the fragment as a whole. As only 12 loci were tested and
considerable variation between the microarray and 5hmC-qPCR
was expected, we hypothesized that assaying additional loci would
result in significant association between the two techniques. Ten
additional loci were assayed by 5hmC-qPCR in the brain and liver
samples. The values from the microarray and 5hmC-qPCR were
now significantly correlated for liver (Pearson’s correlation co-
efficient; r = 0.53, P = 0.01) and approaching significance for brain
(Pearson’s correlation coefficient; r = 0.42, P = 0.051) samples
(Supplemental Fig. S8D).
Unsupervised hierarchical clustering of 5hmC levels at 12
loci in six tissues resulted in grouping the samples into two clusters
corresponding to loci with high levels of 5hmC (the ‘‘HIGH’’
cluster; median 5hmC content = 17.2%) and those with lower
levels of 5hmC (the ‘‘LOW’’ cluster; median 5hmC content =
2.2%). Consistent with the results obtained from the microarrays,
the HIGH cluster consisted entirely of genic MspI sites, primarily
from the H19/IGF2 locus, whereas the LOW cluster consisted of
MspI sites from the HOXA cluster and non-genic MspI sites from
Figure 4. 5hmC is enriched in transcribed regions. (A) Diagram illustrating the defined genomic regions that are assayed for %5hmC enrichment. All
probes foundwithin peaks of 5hmC enrichment were classified according to their genic location. The bar chart below illustrates that probes within peaks of
5hmC (‘‘peak-probes’’) are enriched in intragenic regions in brain and breast tissues. See text for definition of 5hmCpeaks. (B) Bar chart illustrating that the
peak-probes associate with regions of active transcription in brain and breast. The percentage of probes overlapping RNA-sequencing reads for each tissue
is shown. (C ) Box plot showing that 5hmC levels increase with steady-state transcript levels. Each probe was classified according to its number of
overlapping RNA-sequencing reads for brain and breast; none = 0, low = 1, medium = 1–5, high > 5. (D) The presence of 5hmC is associated with
transcription. The HOXA cluster is transcribed and marked with 5hmC in breast, whereas transcription and 5hmC appear absent in brain. Schematic
representation of both the 5hmC and RNA-sequencing profile of the HOXA cluster is shown; the figure is adapted from the UCSC Genome Browser.
Transcription values are given in reads per million (RPM).
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the H19/IGF2 cluster (Fig. 5A). Moreover, a heat map of the clus-
tered samples revealed a striking difference in absolute levels of
5hmC at the same loci between tissues (Fig. 5A). The inter-tissue
variation in 5hmC levels was particularly evident at loci with
higher 5hmC content, the HIGH cluster, with large, highly sig-
nificant (Mann-Whitney U-test, P < 0.01) differences between tis-
sues (Fig. 5B). Indeed, average 5hmC values in brain were more
than 20-fold higher than those observed in blood.
As the pattern of inter-tissue differences in absolute 5hmC
content appeared similar to those previously determined for global
5hmC levels (Fig. 1C), we investigated the relationship between
global 5hmC levels and those determined by locus-specific 5hmC-
qPCR. We found that global 5hmC levels correlated significantly
with 5hmC levels determined for the HIGH cluster loci, LOW
cluster loci, and all loci combined (Fig. 5C). Thus, although we
found a small, but significant correlation between transcript levels
and 5hmC levels within tissues, transcript levels alone could ex-
plain <1% of the variation in 5hmC levels as determined by tiling
microarray (i.e., brain; r2 = 0.0025), whereas relative global 5hmC
levels determined by dot-bot (Fig. 1C) could explain >85% of the
observed inter-tissue variation in 5hmC levels determined by
5hmC-qPCR at all loci (r2 = 0.85) (Fig. 5C).
As the observed inter-tissue differences in absolute 5hmC
content could be explained by large inter-tissue variation in gene
expression, we tested the association of inter-tissue expression and
%5hmC for the H19 and IGF2 loci and found no significant asso-
ciation (Fig. 5D). A similar absence of association was found for
HOXA6 (Spearman’s rho = 0.5, P = 0.45) and HOXA7 (Spearman’s
rho = 0.1, P = 0.95). In a recent study, eight CpGs in the gene bodies
of the EGFR and VANGL1 genes were assayed by 5hmC-qPCR in
four human tissues (brain, heart, spleen, and liver) and HeLa cells
(Kinney et al. 2011). We determined the relative expression of
EGFR and VANGL1 in these tissues by quantitative RT-PCR and,
again, found no correlation between expression and 5hmC con-
tent of the gene body of either the EGFR (Spearman’s rho =0.1, P =
0.95) or VANGL1 (Spearman’s rho = 0.3, P = 0.68) gene (Supple-
mental Fig. S8E). Again, brain contained the highest levels of
5hmC and HeLa cells the least. Thus, these independently de-
termined 5hmC data are completely consistent with our observa-
tion that tissue type is a major modifier of 5hmC content of genes
in humans and that inter-tissue 5hmC levels show no clear asso-
ciation with gene transcription.
Discussion
The discovery of 5-hydroxymethylation
of cytosine as an abundant epigenetic
mark in mammalian genomes has begun
to redefine the field of DNA methylation
and our interpretation of DNA methyla-
tion data past and present, most of which
does not distinguish between canonical
5mC and 5hmC (Nestor et al. 2010). Us-
ing immuno-precipitation of DNA with
a 5hmC-specific antibody, a plethora of
recent studies have begun to describe the
genomic location of 5hmC and the po-
tential function of both the mark and the
TET enzymes that catalyze its generation
from 5mC (Ficz et al. 2011; Pastor et al.
2011; Williams et al. 2011; Wu et al.
2011a,b). All have reported the preferen-
tial genic localization of both TET1 and
5hmC in mouse ES cells; however, any correlation between 5hmC
and transcription levels is less clear. Unexpectedly, a small set of
genes were up-regulated in knockdowns of TET1 in both wild-type
mouse ES cells andmES cells lacking DNAmethylation, suggesting
a role for TET1 in transcriptional repression, which is independent
of its catalytic activity. However, most recent genome-wide studies
have performed very similar experiments, and all in the same
model system, namely, mouse ES cells. A single study of human
brain frontal lobe tissue similarly reported an association of 5hmC
with genic regions and a positive correlation between gene-body
5hmC enrichment and transcription level (Jin et al. 2011). How-
ever, because this study examined only one tissue type and was
restricted to promoter regions of genes, our knowledge of 5hmC
patterns within and between normal mammalian tissues remains
basic.
Here, we present the first systematic study of both global and
locus-specific patterns of 5hmC in normal human tissues and both
cancer- and non-cancer-derived cell lines. Importantly, in addition
to immuno-precipitation-based assays of 5hmC content, we use
sensitive 5hmC-qPCR to quantify absolute levels of 5hmC at sev-
eral loci in numerous tissues. We report large differences in global
5hmC in normal human tissues, consistent with reports of global
5hmC in mouse tissues (Kriaucionis and Heintz 2009). The inter-
tissue difference inglobal 5hmCis striking, brainDNAcontaining>20
times the 5hmC of blood DNA. Indeed, although we show that
transcription level correlates weakly with 5hmC levels within tis-
sues, tissue type, and thus global 5hmC content is a far more
powerful predictor of the 5hmC content in genes (Fig. 5C). Our
failure to find significant correlation between gene expression and
5hmC content between tissues is surprising (Fig. 5D) and suggests
that factors other than transcription are the major modifiers of
genic 5hmC content. In addition, because the observed reduction
in 5hmC across all tissues was broadly conserved at all loci tested,
inter-tissue differences in global 5hmC are most likely due to
a largely equal reduction in 5hmC content across the genome, as
opposed to disproportionate loss at certain genomic elements (i.e.,
repeats).
5hmC is widely presumed to be an intermediate in a process
of DNA demethylation, either active or passive. Assuming a model
of passive demethylation, 5hmC loss resulting from failure to
maintain the mark after DNA replication, one would predict that
tissues with a relatively low proliferation rate (i.e., brain) would
Table 1. 5hmC content (%) at 12 loci in six normal human tissues determined by 5hmC-qPCR
(EpiMark, NEB)
Locus Brain A Breast A Liver A Placenta A Testis B Blood A
H19 genic 3 69.7 22.3 24.7 2.8 14.1 1.3
H19 genic 4 47.8 37.4 10.6 18.7 32.0 4.3
IGF2 genic 1 43.5 14.4 16.8 27.0 47.1 2.7
H19 genic 1 36.7 11.8 14.8 13.0 10.6 0.9
HOXA6 intron 36.2 59.6 27.2 17.5 15.4 1.7
H19 intergenic 13.4 1.2 4.4 1.7 0.9 0.42
HOXA intergenic 10.6 3.7 1.72 0.22 0.5 0.0
HOXA6 exon 9.1 3.9 4.3 7.4 1.4 1.42
H19 promoter 6.8 16.5 12.2 0.3 4.5 1.4
HOXA7 intron 2.6 8.8 3.7 10.1 4.5 –
HOXA intergenic 0.8 4.2 1.1 2.9 0.5 2.2
HOXA7 exon 2.8a 2.9 0.1 0.4 1.9 0.3
All values are single measurements determined by 5hmC-qPCR (EpiMark, NEB). See Supplemental
Figure S1 for experimental outline.
aNegative values were artificially set to 0.1 in analyses and plotting.
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have the highest levels of 5hmC and highly proliferative tissues
and cell lines would contain the least, as is broadly observed (Fig.
1C). Indeed, adaptation of normal breast cells to culture conditions
did result in a decrease in 5hmC levels over time, consistent with
an increase in passive loss of 5hmC due to an increased pro-
liferation rate in culture (Fig. 2E). However, a simultaneous down-
regulation of TET1/2/3 gene expression was also observed, sug-
gesting that the reduction in 5hmC was due to both passive loss
and reduced production of 5hmC (Fig. 2C,E). Irrespective of the
mechanism of TET repression and 5hmC loss in culture, this
finding highlights the marked difference in 5hmC biology be-
tween cell lines and their tissues of origin. Further study of the loss
of 5hmC upon transformation of tissues to cell culture may offer
a useful tool in dissecting 5hmC biology in mammals.
We also report a dramatic reduction of global 5hmC levels and
TET1/2/3 gene expression in breast cancer cell lines comparedwith
normal breast tissue (Fig. 2A–D). This observation is particularly
interesting, given that breast cancer cell lines possess extensive
aberrant promoter hypermethylation, and these promoters are
enriched for CpG Island promoters marked simultaneously by
H3K4me3 and H3K27me3 (bivalent promoters) in ES cells, the
same class of genes identified as being marked by TET1 occupancy
in mouse ES cells (Ohm et al. 2007; Sproul et al. 2011; Williams
et al. 2011).
In summary, our results reveal that tissue type is a major
modifier of both global and locus-specific 5hmC at genes in nor-
mal human tissues, suggesting that the functional importance of
5hmC varies between tissues. We also show that cell culture is re-
fractory to both TET1/2/3 gene expression and maintenance of
global 5hmCcontent. Our study emphasizes the importance of the
model system (tissue or cell line) used to study 5hmC and the
pressing need for more practicable quantitative assays of 5hmC.
Figure 5. Tissue type is a major modifier of 5hmC levels in genes. (A) Unsupervised hierarchical clustering of 12 loci by absolute 5hmC levels results in
two groups containing high (HIGH) and low (LOW) levels of 5hmC, respectively, for each indicated tissue. (Red boxes) H19/IGF2 loci; (blue boxes) HOXA
loci. (B) Box-plot of 5hmC (%) levels of all five loci in the HIGH cluster for each tissue shows that the range of 5hmC levels at HIGH loci varies markedly
between tissues. (C ) The relative global 5hmC content (Fig. 1C) correlates with average 5hmC (%) content of each tissue as determined by 5hmC-qPCR.
(D) Inter-tissue differences in 5hmC levels do not correlate with inter-tissue expression levels. Average 5hmC (%) content of genic loci of H19 (upper panel)
and IGF2 (lower panel) in each indicated tissue is plotted against expression of probes (H19 = 1 probe; IGF2 = 2 probes) for each gene obtained from the
GNF expression database. The GNF expression database does not contain data for breast.
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Methods
Ethics statement
The use of human breast materials from the Edinburgh Breast Unit
at the Western General Hospital was approved by the Lothian
Research Ethics Committee (08/S1101/41).
DNA, RNA, and tissue samples
Normal human tissue DNA samples were purchased from AMS
Biotechnology Ltd. unless stated otherwise. Normal human tissue
RNA samples were purchased from Applied Biosystems. SHEF-6
human embryonic stem cell DNA and RNAwas a kind gift fromDr.
David Hay (Center for Regenerative Medicine, Edinburgh, UK)
(Aflatoonian et al. 2010). Clinical specimens of normal human
breast tissue were obtained through the Edinburgh Experimental
Cancer Medicine Center. Sample details are given in Supplemental
Table S1. DNA and RNA were isolated from cell lines using the
QIAGEN AllPrep DNA/RNA/Protein Mini Kit.
Cell culture
All human breast cancer cell lines were cultured as per Neve et al.
(2006). HepG2,HCT116, and SW480 cells were cultured inDMEM,
McCoys 5A and Leibovitz’s L-15 medium, respectively, supple-
mented with 10% fetal calf serum (FCS). Human mammary epi-
thelial cell (HMEC) lines were established from normal human
breast tissue as previously described (Holliday et al. 2009). Sub-
sequently, HMECsweremaintained in CnT22medium (CellnTEC)
supplemented with 10% FCS.
DNA dot-blotting
DNA samples were added to denaturation buffer (0.4 mM NaOH,
10 mM EDTA) and denatured for 10 min at 100°C. Samples were
rapidly chilled for 5min onwet ice and then applied to a positively
charged nylon membrane under vacuum using a 96-well Dot Blot
Hybridisation Manifold (Harvard Apparatus Limited). The mem-
brane was washed twice in 23 SSC buffer, UV-cross-linked, and
dried for 1 h at 70°C. Duplicate membranes were probed with
antibodies specific to 5mC (Eurogenentec; dilution factor 1:2000)
and 5hmC (Active Motif; dilution factor 1:8000). To control for
loading, duplicate membranes were probed with a rabbit poly-
clonal antibody raised against single-stranded DNA (Demeditec
Diagnostics). Subsequently, membranes were probed with either
a rabbit (a-5hmC and a-ssDNA membranes) or mouse (a-5mC
membranes) IgG antibody conjugated to horseradish peroxidase
(HRP). Following treatment with enhanced chemiluminescence
(ECL) substrate, membranes were scanned on an ImageQuant LAS
4000 (GE Healthcare) imaging station. Spot intensity was quanti-
fied using ImageJ image processing and analysis software (NIH).
Immunoprecipitation and genomic mapping
5mC- and 5hmC- containing DNA fragments
Genomic DNA (5hmC-IP; 2.5 mg in 450 mL of TE), sonicated to
yield a fragment distribution of ;300–1000 bp, was denatured by
incubation for 10 min at 100°C. Samples were rapidly chilled on
wet ice. At this point, 45 mL (10%) of denatured sample was re-
moved and saved as input, and 45mL of 103 IP buffer (100mMNa-
Phosphate at pH 7.0 [mono and dibasic], 1.4 M NaCl, 0.5% Triton
X-100) and 1 mg of a-5hmC (ActiveMotif; #39769) antibody were
added to the remaining sample. Samples were incubated overnight
at 4°C with gentle agitation. Then, 40 mL of magnetic beads
(Dynabeads Protein G; Invitrogen) in 13 IP buffer was added to
each sample to allowmagnetic separation of the antibody from the
unbound DNA using a magnetic tube rack. Samples were in-
cubated for 1 h at 4°C with gentle agitation. Beads were collected
with a magnetic rack and washed with 1000 mL of 13 IP buffer for
10 min at room temperature with gentle agitation; washing was
repeated three times. Beads were collected with a magnetic rack
and resuspended in 250 mL of digestion buffer (50 mM Tris at pH
8.0, 10 mM EDTA, 0.5% SDS) followed by addition of 10 mL of
proteinase K (20 mg/mL; Roche Applied Science) and incubation
for 1.5 h at 52°Cwith constant shaking ($800 rpm). Finally, beads
were removed using a magnetic rack, and DNA was purified from
the remaining sample using a QIAquick PCR Purification Kit
(QIAGEN), eluting in a final volume of 40 mL of dH2O. Inputs were
also purified using a QIAquick PCR Purification Kit and eluted in
40 mL of dH2O.
Subsequently, 10 ng of input and IP DNA was subjected to
whole genome amplification (WGA) using the GenomePlex
CompleteWholeGenomeAmplificationKit (Sigma-Aldrich) as per
themanufacturer’s instructions. AmplifiedDNAwas run on a 1.2%
agarose gel to confirm consistency of fragment size between sam-
ples. Subsequently, amplified DNA samples were Cy5- (IP) or Cy3-
(Input) labeled by random priming using the Dual-Color DNA
Labeling Kit (NimbleGen). Labeled samples were applied to a Hu-
man DNA Methylation 4x72K ENCODE HG17 Targeted Tiling
Array, which tiles the biologically significant ENCODE regions
(EN001–EN014), and hybridized overnight at 42°C. Slides were
washed and scanned as per the NimbleGen protocol.
Analysis of microarray data
All analysis of NimbleGen microarray data was performed using
custom-written scripts implemented in the statistical program-
ming language R. Due to differences in the saturation kinetics of
the dyes used to label the input and IP samples, the absolute en-
richment values of a probe (M) often show a dependency on the
average intensity of the probe across the input and IP (A). To cor-
rect for this bias, each array was subjected to locally weighted
scatterplot smoothing (Loess normalization) (Cleveland 1979).
Subsequently, scale normalization was used to normalize values of
M between arrays of replicate samples. Finally, the data were
smoothed using a running median in a sliding window of 13
probes. A peak of 5hmC was defined as any region of five con-
secutive probes in which at least four probes had an enrichment
value greater than the 75th percentile. This definition of a peak
resulted in a false discovery rate of 0.017. All R-scripts are available
upon request. Although themicroarrays were designed against the
hg17 version of the human genome assembly, all coordinates were
mapped to version hg18 to allow comparison with RNA-sequenc-
ing data. Conversion of genomic coordinates between genome
assemblies was performed using the ‘‘liftOver’’ tool downloaded
from the UCSC Genome Browser.
Previously published RNA-sequencing data for normal hu-
man breast, brain, colon, liver, and testis were downloaded from
the UCSC Genome Browser (Ramskold et al. 2009). RNA-seq data
were used in their normalized form expressed as reads per million
(RPM). Probes were designated as in a transcribed region if they
overlapped a sequencing read by one ormore base pairs.Where the
density of reads overlapping a probe varied across the length of the
probe, the average density was used.
Absolute quantification of 5-hmC and 5-mC levels at specific
CpG dinulceotides
Absolute levels of 5hmC, 5mC, and C at specific MspI sites were
quantified using the EpiMark 5-hmC and 5-mC Analysis Kit
Tissue specificity of 5hmC content and patterns
Genome Research 475
www.genome.org
(#E3317S; New England BioLabs) followed by quantitative PCR
(qPCR). An outline of the assay and sample calculations are pre-
sented in Supplemental Figure S1. Briefly, DNA is treated with T4
b-glucosyltransferase (T4-BGT), which specifically glucosylates
5-hydroxymethylcytosine to yield b-glucosyl-5hmC (5ghmC).
Whereas MspI is capable of cleaving its recognition sequence
containing either 5mC (C5mCGG) or 5hmC (C5hmCGG), cleav-
age is blocked by 5ghmC (C5ghmCGG). qPCR is used to determine
the amount of DNA template cut by MspI before and after treat-
ment with T4-BGT, allowing estimation of the absolute 5hmC
levels at the MspI site. The oligonucleotide primer sequences used
are listed in Supplemental Table S2A.
RNA extraction, cDNA synthesis, and quantitative reverse
transcriptase PCR
RNAwas extracted from cell lines using TRIzol reagent (Invitrogen)
or an RNeasy Mini kit (QIAGEN) according to the manufacturers’
instructions. A Superscript II Reverse transcriptase kit (Invitrogen)
was used to make complementary DNA from 500 ng of total RNA.
All qRT-PCRs were carried out at an annealing temperature 58°C in
a LightCycler 480 Real-Time PCR System (Roche Applied Science).
Primer sequences are given in Supplemental Table S2B.
Data access
All microarray data have been submitted to the NCBI Gene Ex-
pression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/)
under accession number GSE33219.
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